# Thousand Oaks Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thousand-oaks-biopharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Nantong, China
- Website: www.tobiopharm.com
- Total disclosed funding: $169M
- Latest round: Series C (Aug 29, 2021)
- Investors on record: 24

## About

Established in 2017 and based in Nantong, China, Thousand Oaks Biopharmaceuticals, Inc. is a biopharmaceutical technology service provider that focuses on biopharmaceuticals in the fields of CRO and CMO. In 2019, the company established Thounsand Oaks Biopharmaceuticals, Inc. in the US. In 2020, the company produced COVID-19 vaccines. Dr. Shun luo, the founder and chairman of the company, worked at Serono, JRH Biosciences and Amgen.

The company engages in the development of CDMO biopharmaceutical products. Its main products include a transient transfection platform, stock solutions and preparation filling, etc. The transient transfection platform provides proteins for drug screening and druggability evaluation research.

In the future, the company will focus on recombinant protein, virus, nucleic acid, ADC and other fields to provide a one-stop CMC overall solution for biopharmaceutical customers.

## Funding rounds

- Series C, Aug 29, 2021 — Hillhouse Investment, Beyond Capital, Timesbole Venture Capital, Fortune Haven Capital, Northeast Ronghui Securities Asset Management, Green Waters Fund
- Series C, Mar 10, 2021, $61M — CDH Investments, China International Capital Corporation, China Venture Capital, HighLight Capital, Fosun Capital, Asia Green Fund, Goldstone Investment, GL Ventures, Trinity Innovation Fund
- Series B, Jul 23, 2020, $64M — CCB International Asset Management, China International Capital Corporation, Wens Capital, Shanghai Huaxu Investment, Goldstone Investment
- Series A, Jan 1, 2019, $44M — Beyond Capital, New Alliance Capital, Qianrong Capital, Addor Capital, Sumin Investment, Jilin Aodong Pharmaceutical Group Co., Ltd, Blue Bay Capital

## Investors

- Beyond Capital — Series A, Series C
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A
- Qianrong Capital (https://capitalatlas.ai/funds/qianrong-capital) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Sumin Investment (https://capitalatlas.ai/funds/sumin-investment) — Series A
- Jilin Aodong Pharmaceutical Group Co., Ltd — Series A
- Blue Bay Capital — Series A
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B, Series C
- Wens Capital (https://capitalatlas.ai/funds/wens-capital) — Series B
- Shanghai Huaxu Investment — Series B
- Goldstone Investment — Series B, Series C
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series C
- China Venture Capital (https://capitalatlas.ai/funds/china-venture-capital) — Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series C
- Fosun Capital (https://capitalatlas.ai/funds/fosun-capital) — Series C
- Asia Green Fund (https://capitalatlas.ai/funds/asia-green-fund) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Timesbole Venture Capital (https://capitalatlas.ai/funds/timesbole-venture-capital) — Series C
- Fortune Haven Capital (https://capitalatlas.ai/funds/fortune-haven-capital) — Series C
- Northeast Ronghui Securities Asset Management — Series C
- Green Waters Fund — Series C